Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
Cost of Sales: $61 million for Q3 2024, compared to $99 million in Q3 2023. R&D and SG&A Expenses: $158 million for Q3 2024, a 26% reduction from Q3 2023. Cash Position: Over $1 billion in cash and accounts receivables at the end of Q3 2024. Revised Full Year 2024 Revenue Guidance: $650 million to $700 million. Revised Full Year 2024 Product Sales Guidance: $175 million to $225 million. Licensing, Royalties, and Other Revenue Guidance: Increased to $475 million for full year 2024. Future Milestones: Up to $700 million in near-term COVID-19 and flu/COVID combination milestones under the Sanofi Agreement. Warning! GuruFocus has detected 4 Warning Signs with NVAX. Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Novavax Inc ( NASDAQ:NVAX ) has established a strategic partnership with Sanofi, which will lead to double-digit royalties from Sanofi's sales of the COVID-19 vaccine starting
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAXAccesswire
- How Technology Makes The CFO's Job More About Driving Value [Forbes]Forbes
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAXPR Newswire
- How Health, Innovation And A Bit Of Friction Help Pharmavite Succeed [Forbes]Forbes
- NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.Accesswire
NVAX
Earnings
- 11/12/24 - Beat
NVAX
Sec Filings
- 11/20/24 - Form 8-K
- 11/13/24 - Form 4
- 11/13/24 - Form 3
- NVAX's page on the SEC website